Canada approves Evusheld for prevention drug for immunocompromised patients

Ottawa: Canada has AstraZeneca’s (NASDAQ:AZN) antibody-based cocktail Evusheld vaccine for the prevention of COVID-19 and to boost immunity in people. This drug will strengthen immunity against corona in adults and children, officials said.

Canadian health department said that after a thorough and independent scientific study of the vaccine, the Department has approved that Evusheld meets Canada’s stringent safety, efficacy and quality requirements.

Meanwhile, now this vaccine is for use in adults and children (12 years of age and older, weighing at least 40 kg) who are not currently infected with COVID-19 or recently known contact with someone infected with coronavirus.